Source comparison
Thymosin Alpha-1: FDA Approved Status Comparison
FDA Marketing Approval Not approved. Investigational status only Approved in 35+ countries (Italy, China, Russia, South Korea, others) as Zadaxin/Thymalfasin International: national regulatory authority approval (EMA, NMPA, etc.) based on clinical trial data m
This comparison does not assign a generated winner or score.
- FDA Marketing Approval
- Not approved. Investigational status only
- Approved in 35+ countries (Italy, China, Russia, South Korea, others) as Zadaxin/Thymalfasin
- International: national regulatory authority approval (EMA, NMPA, etc.) based on clinical trial data meeting local standards
- U.S.: research/compounding only; International: prescription medication
- Orphan Drug Designation
- Granted in 2001 for hepatitis B, hepatitis C, DiGeorge syndrome, malignant melanoma
- Not applicable (orphan designation is U.S.-specific)
- FDA orphan designation provides development incentives but does not equal approval
- Designation grants no prescribing authority. Remains investigational
- Evidence Base for Efficacy
- 200+ published trials including Phase II data; no completed U.S. Phase III pivotal trials
- Same trial data underpins international approvals. Primarily Phase II and III trials conducted in China, Italy, Russia
- FDA requires ≥2 pivotal Phase III RCTs; international approvals accepted smaller Phase II/III trials with less stringent controls
- International physicians prescribe based on approved indications; U.S. researchers cite investigational status
- Commercial Availability
- Available only through: (1) IRB-approved research protocols, (2) compounding pharmacies as custom preparations, (3) research suppliers like Real Peptides
- Manufactured and distributed as Zadaxin by RegeneRx Biopharmaceuticals (licensed from Vir Biotechnology); standard prescription medication
- U.S.: no commercial product; International: branded pharmaceutical product with standardised dosing
- International: covered by insurance in some jurisdictions; U.S.: out-of-pocket research/compounding cost
- Bottom Line / Professional Assessment
- Thymosin alpha-1 is not FDA-approved and remains investigational. Orphan designation is a development incentive, not market clearance. Domestic access requires research protocols or compounded preparations.
- Thymosin alpha-1 is a legally approved, clinically used medication in much of the world with decades of post-marketing data. The international-U.S. regulatory gap reflects differing evidentiary standards and lack of commercial incentive to complete U.S. trials, not lack of clinical evidence.
- The peptide's regulatory limbo in the U.S. stems from economics, not science. No sponsor has funded the Phase III trials FDA requires, despite robust international approval and use.